The next generation of biotech blockbusters

The 2007 rate of new biologic approvals was slow, with only a handful of drugs squeaking through FDA review. But the pace is set to pick up in 2008. According to IMS Health, four biologics could receive FDA approval this year if they don't hit any stumbling blocks. Each of the drugs on this list has the potential for over a billion dollars in sales if all goes according to plan. Report

Suggested Articles

It’s final: England won’t be covering AZ’s quick-selling Tagrisso in previously untreated non-small cell lung cancer patients with EGFR mutatations.

Top J&J meds have managed to hang onto market share in the face of new generics and biosims, but the drugmaker expects the pain to continue in 2020.

Lonza’s search for a new CEO is expected to be wrapped up this year as the CDMO homes in on a list of veterans from outside the company.